Rapport Therapeutics, Inc.: Cormorant Asset Management, LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Cormorant Asset Management amended its Schedule 13G filing for Rapport Therapeutics, disclosing a revised passive stake in the clinical-stage biotech. The filing, submitted under SEC accession 0001172661-26-005299, updates the investment firm's previously reported ownership position. Schedule 13G amendments are typically triggered when a holder's stake crosses 5% thresholds or when previously reported figures change materially. The revision matters because it signals a shift in Cormorant's exposure to Rapport, a company developing precision medicines for neurological disorders. Investors will watch for further 13G or 13D filings to gauge whether Cormorant's position continues to change.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Cormorant Asset Management, LP, Rapport Therapeutics, Inc.